Ultragenyx (RARE)
What the price implies
A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.
Fundamental grade
Five factors scored 1 to 9 from RARE's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.
Key numbers
Results from SEC filings
Fiscal years, from Ultragenyx's 10-K filings. Ten years of the full income statement, balance sheet and cash flow.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $351M | $363M | $434M | $560M | $673M |
| Net income | -$454M | -$707M | -$607M | -$569M | -$575M |
| Free cash flow | -$412M | -$497M | -$519M | -$421M | -$472M |
| EPS (diluted) | -$6.70 | -$10.12 | -$8.25 | -$6.29 | -$5.83 |
| Operating margin | -108.6% | -178.6% | -131.1% | -95.7% | -79.5% |
Where the revenue comes from
Revenue by products, fiscal 2025. Every breakdown, year by year.
Superinvestors who own RARE
From each investor's latest 13F filing (what a 13F shows). 1 of the investors we track hold it.
| Investor | Last quarter | Value | % of portfolio | Quarter |
|---|---|---|---|---|
| Cliff Asness AQR Capital Management |
Added | $214M | 0.08% | Q2 2026 |
Insider buying
Open-market purchases by Ultragenyx's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you. Every purchase since records began.
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Mar 3, 2026 | Gilbert Ray Cisneros, Jr. |
0 | $22.07 | — |
| Mar 3, 2026 | Gilbert Ray Cisneros, Jr. |
0 | $22.07 | — |
| Feb 18, 2026 | Gilbert Ray Cisneros, Jr. |
0 | $20.45 | — |
| Feb 18, 2026 | Gilbert Ray Cisneros, Jr. |
0 | $20.45 | — |
Get an alert at your buy price
Pick the price you'd be interested at. We'll email you when RARE trades at or below it.
New accounts get 7 days of Pro, price alerts included. No card needed.
In the full deep dive
Questions
Are Ultragenyx insiders buying the stock?
4 open-market insider purchases of RARE in the last 12 months, from SEC Form 4 filings.
Which superinvestors own Ultragenyx?
1 of the superinvestors Investingly tracks hold RARE in their latest 13F, including Cliff Asness.
Companies like Ultragenyx
All Healthcare stocks · Biotechnology stocks · Stock lists
Prices and ratios as of Oct 11, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.